Team

Pavel brings deep financial and strategic expertise from experiences at Sarissa Capital Management, Credit Suisse’s healthcare investment banking, and biopharmaceutical consulting at McKinsey & Company and BCG. He holds a BA from Harvard and an MBA from Columbia University.

Joining Innoviva in 2014, Marianne previously served as Corporate Controller for three tech companies. A member of the AICPA and the CalCPA, she also served on the CalCPA Peninsula Silicon Valley Chapter board. Marianne holds a BS in Business Administration from San Francisco State University.

Dr. Ronsheim has led teams in development, CMC, and supply chain across various formulations and disease areas at Enanta Pharmaceuticals, Merck/Cubist, and Forest Laboratories. He holds a BS from Southern Connecticut State University and a PhD in Synthetic Organic Chemistry from the University of New Hampshire.

Before joining Innoviva, Christine was CCO at SCYNEXIS and held leadership roles at Paratek. She has also led marketing and sales teams at Wyeth-Ayerst Global Pharmaceuticals, Endo, and Auxilium Pharmaceuticals. She holds a BA from West Chester University and an MBA from Eastern University.

Mr. Basso brings more than 30 years of experience of financial leadership, primarily in the pharmaceutical industry. Prior to joining Innoviva, Mr. Basso served as the Chief Financial Officer and Chief Operating Officer at Cybrexa Therapeutics and has held a variety of financial leadership positions at Inozyme Pharma, Alexion Pharmaceuticals and Pfizer. He received a BS in business from Providence College and an MBA from Boston College.

Dr. Koziel joined us in 2023 from Axcella Therapeutics, where she was Chief Medical Officer. She has previous leadership roles at Novartis Institutes for Biomedical Research, Vertex and Kaleido. She was also a Professor of Medicine, having positions at Harvard Medical School and the University of Massachusetts, with over 90 publications in leading peer reviewed journals. She has a BA and MD from Dartmouth.